Baidu
map

PD-1单抗Keytruda单一疗法显著延长头颈癌患者生存期

2018-07-26 MedSci MedSci原创

默沙东(MSD)的Keytruda作为单一疗法,用于PD-L1阳性的复发或转移性头颈部鳞状细胞癌(HNSCC)患者的一线治疗时,显着延长了患者的总体存活率。

默沙东(MSD)的Keytruda作为单一疗法,用于PD-L1阳性的复发或转移性头颈部鳞状细胞癌(HNSCC)患者的一线治疗时,显著延长了患者的总体存活率。

根据独立数据监测委员会(DMC)对关键性III期KEYNOTE-048试验进行的中期结果分析显示,与目前HNSCC的一线治疗标准(西妥昔单抗联用铂类化疗药物和5-氟尿嘧啶)相比,单用Keytruda(pembrolizumab)可显著延长患者总体生存率。

该公司补充提到,到中期分析时,Keytruda在表达PD-L1(CPS≥20)HNSCC患者中尚未达到无进展生存期(PFS)的主要终点。

默克研究实验室首席医疗官Roy Baynes博士表示:“KEYNOTE-048试验的中期分析表明,Keytruda单药治疗具有很大的潜力用来治疗PD-L1高表达的头颈癌患者。”

这些结果将在即将召开的医学会议上公布,并提交给全球监管机构。

Keytruda已经被批准用于治疗铂类化疗药物后复发或转移的HNSCC的患者。

原始出处:


此文系梅斯医学(MedSci)原创整理编译,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1709074, encodeId=41e01e0907469, content=<a href='/topic/show?id=e50536093aa' target=_blank style='color:#2F92EE;'>#单一疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36093, encryptionId=e50536093aa, topicName=单一疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba7e31580307, createdName=thinkibmz_44722604, createdTime=Thu Mar 28 23:55:00 CST 2019, time=2019-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932631, encodeId=441b19326311c, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Thu Feb 21 06:55:00 CST 2019, time=2019-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336856, encodeId=56e6336856cb, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7ceOChkqicg6SzjqymjoEtLx55A9HNpmV1quNDdicpmTPZp1WXCq35u64iaCjRhibmrEPN5JHdvOZt9Ajj4MxzLbJ9/0, createdBy=ddf3111026, createdName=jawel, createdTime=Mon Aug 06 17:51:20 CST 2018, time=2018-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295889, encodeId=ae6b129588923, content=<a href='/topic/show?id=f30a4441598' target=_blank style='color:#2F92EE;'>#头颈癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44415, encryptionId=f30a4441598, topicName=头颈癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Sat Jul 28 00:55:00 CST 2018, time=2018-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1346836, encodeId=7c52134683662, content=<a href='/topic/show?id=97141390e89' target=_blank style='color:#2F92EE;'>#PD-1单抗KEYTRUDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13907, encryptionId=97141390e89, topicName=PD-1单抗KEYTRUDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f76619, createdName=gj0731, createdTime=Sat Jul 28 00:55:00 CST 2018, time=2018-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364847, encodeId=a172136484ec4, content=<a href='/topic/show?id=da511390508' target=_blank style='color:#2F92EE;'>#PD-1单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13905, encryptionId=da511390508, topicName=PD-1单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Sat Jul 28 00:55:00 CST 2018, time=2018-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378184, encodeId=f65613e818483, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Jul 28 00:55:00 CST 2018, time=2018-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334299, encodeId=0d6c334299dd, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfBfgWn9nXBgH1sNSiaOAKhsKpN40jDHQKqcRzovau5VibLvREN8uxnu9sKoScBicHSiaDMmbveibFdrBiaD4k4IOPwlG/0, createdBy=b5d11730951, createdName=Jackie Li, createdTime=Thu Jul 26 11:48:46 CST 2018, time=2018-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334288, encodeId=efee334288eb, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfDEeydJz0GlP8O0ngrUX6AYCXFic0XDOOAyeQicIqnOd4TrWSwiagJrsFNYuWC1Uc6iavbS1hWt9xtZAhAqLGHqZyl/0, createdBy=42891977006, createdName=1e17414fm02(暂无匿称), createdTime=Thu Jul 26 10:02:51 CST 2018, time=2018-07-26, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1709074, encodeId=41e01e0907469, content=<a href='/topic/show?id=e50536093aa' target=_blank style='color:#2F92EE;'>#单一疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36093, encryptionId=e50536093aa, topicName=单一疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba7e31580307, createdName=thinkibmz_44722604, createdTime=Thu Mar 28 23:55:00 CST 2019, time=2019-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932631, encodeId=441b19326311c, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Thu Feb 21 06:55:00 CST 2019, time=2019-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336856, encodeId=56e6336856cb, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7ceOChkqicg6SzjqymjoEtLx55A9HNpmV1quNDdicpmTPZp1WXCq35u64iaCjRhibmrEPN5JHdvOZt9Ajj4MxzLbJ9/0, createdBy=ddf3111026, createdName=jawel, createdTime=Mon Aug 06 17:51:20 CST 2018, time=2018-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295889, encodeId=ae6b129588923, content=<a href='/topic/show?id=f30a4441598' target=_blank style='color:#2F92EE;'>#头颈癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44415, encryptionId=f30a4441598, topicName=头颈癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Sat Jul 28 00:55:00 CST 2018, time=2018-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1346836, encodeId=7c52134683662, content=<a href='/topic/show?id=97141390e89' target=_blank style='color:#2F92EE;'>#PD-1单抗KEYTRUDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13907, encryptionId=97141390e89, topicName=PD-1单抗KEYTRUDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f76619, createdName=gj0731, createdTime=Sat Jul 28 00:55:00 CST 2018, time=2018-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364847, encodeId=a172136484ec4, content=<a href='/topic/show?id=da511390508' target=_blank style='color:#2F92EE;'>#PD-1单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13905, encryptionId=da511390508, topicName=PD-1单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Sat Jul 28 00:55:00 CST 2018, time=2018-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378184, encodeId=f65613e818483, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Jul 28 00:55:00 CST 2018, time=2018-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334299, encodeId=0d6c334299dd, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfBfgWn9nXBgH1sNSiaOAKhsKpN40jDHQKqcRzovau5VibLvREN8uxnu9sKoScBicHSiaDMmbveibFdrBiaD4k4IOPwlG/0, createdBy=b5d11730951, createdName=Jackie Li, createdTime=Thu Jul 26 11:48:46 CST 2018, time=2018-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334288, encodeId=efee334288eb, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfDEeydJz0GlP8O0ngrUX6AYCXFic0XDOOAyeQicIqnOd4TrWSwiagJrsFNYuWC1Uc6iavbS1hWt9xtZAhAqLGHqZyl/0, createdBy=42891977006, createdName=1e17414fm02(暂无匿称), createdTime=Thu Jul 26 10:02:51 CST 2018, time=2018-07-26, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1709074, encodeId=41e01e0907469, content=<a href='/topic/show?id=e50536093aa' target=_blank style='color:#2F92EE;'>#单一疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36093, encryptionId=e50536093aa, topicName=单一疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba7e31580307, createdName=thinkibmz_44722604, createdTime=Thu Mar 28 23:55:00 CST 2019, time=2019-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932631, encodeId=441b19326311c, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Thu Feb 21 06:55:00 CST 2019, time=2019-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336856, encodeId=56e6336856cb, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7ceOChkqicg6SzjqymjoEtLx55A9HNpmV1quNDdicpmTPZp1WXCq35u64iaCjRhibmrEPN5JHdvOZt9Ajj4MxzLbJ9/0, createdBy=ddf3111026, createdName=jawel, createdTime=Mon Aug 06 17:51:20 CST 2018, time=2018-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295889, encodeId=ae6b129588923, content=<a href='/topic/show?id=f30a4441598' target=_blank style='color:#2F92EE;'>#头颈癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44415, encryptionId=f30a4441598, topicName=头颈癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Sat Jul 28 00:55:00 CST 2018, time=2018-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1346836, encodeId=7c52134683662, content=<a href='/topic/show?id=97141390e89' target=_blank style='color:#2F92EE;'>#PD-1单抗KEYTRUDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13907, encryptionId=97141390e89, topicName=PD-1单抗KEYTRUDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f76619, createdName=gj0731, createdTime=Sat Jul 28 00:55:00 CST 2018, time=2018-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364847, encodeId=a172136484ec4, content=<a href='/topic/show?id=da511390508' target=_blank style='color:#2F92EE;'>#PD-1单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13905, encryptionId=da511390508, topicName=PD-1单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Sat Jul 28 00:55:00 CST 2018, time=2018-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378184, encodeId=f65613e818483, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Jul 28 00:55:00 CST 2018, time=2018-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334299, encodeId=0d6c334299dd, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfBfgWn9nXBgH1sNSiaOAKhsKpN40jDHQKqcRzovau5VibLvREN8uxnu9sKoScBicHSiaDMmbveibFdrBiaD4k4IOPwlG/0, createdBy=b5d11730951, createdName=Jackie Li, createdTime=Thu Jul 26 11:48:46 CST 2018, time=2018-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334288, encodeId=efee334288eb, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfDEeydJz0GlP8O0ngrUX6AYCXFic0XDOOAyeQicIqnOd4TrWSwiagJrsFNYuWC1Uc6iavbS1hWt9xtZAhAqLGHqZyl/0, createdBy=42891977006, createdName=1e17414fm02(暂无匿称), createdTime=Thu Jul 26 10:02:51 CST 2018, time=2018-07-26, status=1, ipAttribution=)]
    2018-08-06 jawel

    学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1709074, encodeId=41e01e0907469, content=<a href='/topic/show?id=e50536093aa' target=_blank style='color:#2F92EE;'>#单一疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36093, encryptionId=e50536093aa, topicName=单一疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba7e31580307, createdName=thinkibmz_44722604, createdTime=Thu Mar 28 23:55:00 CST 2019, time=2019-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932631, encodeId=441b19326311c, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Thu Feb 21 06:55:00 CST 2019, time=2019-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336856, encodeId=56e6336856cb, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7ceOChkqicg6SzjqymjoEtLx55A9HNpmV1quNDdicpmTPZp1WXCq35u64iaCjRhibmrEPN5JHdvOZt9Ajj4MxzLbJ9/0, createdBy=ddf3111026, createdName=jawel, createdTime=Mon Aug 06 17:51:20 CST 2018, time=2018-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295889, encodeId=ae6b129588923, content=<a href='/topic/show?id=f30a4441598' target=_blank style='color:#2F92EE;'>#头颈癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44415, encryptionId=f30a4441598, topicName=头颈癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Sat Jul 28 00:55:00 CST 2018, time=2018-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1346836, encodeId=7c52134683662, content=<a href='/topic/show?id=97141390e89' target=_blank style='color:#2F92EE;'>#PD-1单抗KEYTRUDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13907, encryptionId=97141390e89, topicName=PD-1单抗KEYTRUDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f76619, createdName=gj0731, createdTime=Sat Jul 28 00:55:00 CST 2018, time=2018-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364847, encodeId=a172136484ec4, content=<a href='/topic/show?id=da511390508' target=_blank style='color:#2F92EE;'>#PD-1单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13905, encryptionId=da511390508, topicName=PD-1单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Sat Jul 28 00:55:00 CST 2018, time=2018-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378184, encodeId=f65613e818483, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Jul 28 00:55:00 CST 2018, time=2018-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334299, encodeId=0d6c334299dd, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfBfgWn9nXBgH1sNSiaOAKhsKpN40jDHQKqcRzovau5VibLvREN8uxnu9sKoScBicHSiaDMmbveibFdrBiaD4k4IOPwlG/0, createdBy=b5d11730951, createdName=Jackie Li, createdTime=Thu Jul 26 11:48:46 CST 2018, time=2018-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334288, encodeId=efee334288eb, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfDEeydJz0GlP8O0ngrUX6AYCXFic0XDOOAyeQicIqnOd4TrWSwiagJrsFNYuWC1Uc6iavbS1hWt9xtZAhAqLGHqZyl/0, createdBy=42891977006, createdName=1e17414fm02(暂无匿称), createdTime=Thu Jul 26 10:02:51 CST 2018, time=2018-07-26, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1709074, encodeId=41e01e0907469, content=<a href='/topic/show?id=e50536093aa' target=_blank style='color:#2F92EE;'>#单一疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36093, encryptionId=e50536093aa, topicName=单一疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba7e31580307, createdName=thinkibmz_44722604, createdTime=Thu Mar 28 23:55:00 CST 2019, time=2019-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932631, encodeId=441b19326311c, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Thu Feb 21 06:55:00 CST 2019, time=2019-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336856, encodeId=56e6336856cb, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7ceOChkqicg6SzjqymjoEtLx55A9HNpmV1quNDdicpmTPZp1WXCq35u64iaCjRhibmrEPN5JHdvOZt9Ajj4MxzLbJ9/0, createdBy=ddf3111026, createdName=jawel, createdTime=Mon Aug 06 17:51:20 CST 2018, time=2018-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295889, encodeId=ae6b129588923, content=<a href='/topic/show?id=f30a4441598' target=_blank style='color:#2F92EE;'>#头颈癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44415, encryptionId=f30a4441598, topicName=头颈癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Sat Jul 28 00:55:00 CST 2018, time=2018-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1346836, encodeId=7c52134683662, content=<a href='/topic/show?id=97141390e89' target=_blank style='color:#2F92EE;'>#PD-1单抗KEYTRUDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13907, encryptionId=97141390e89, topicName=PD-1单抗KEYTRUDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f76619, createdName=gj0731, createdTime=Sat Jul 28 00:55:00 CST 2018, time=2018-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364847, encodeId=a172136484ec4, content=<a href='/topic/show?id=da511390508' target=_blank style='color:#2F92EE;'>#PD-1单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13905, encryptionId=da511390508, topicName=PD-1单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Sat Jul 28 00:55:00 CST 2018, time=2018-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378184, encodeId=f65613e818483, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Jul 28 00:55:00 CST 2018, time=2018-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334299, encodeId=0d6c334299dd, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfBfgWn9nXBgH1sNSiaOAKhsKpN40jDHQKqcRzovau5VibLvREN8uxnu9sKoScBicHSiaDMmbveibFdrBiaD4k4IOPwlG/0, createdBy=b5d11730951, createdName=Jackie Li, createdTime=Thu Jul 26 11:48:46 CST 2018, time=2018-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334288, encodeId=efee334288eb, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfDEeydJz0GlP8O0ngrUX6AYCXFic0XDOOAyeQicIqnOd4TrWSwiagJrsFNYuWC1Uc6iavbS1hWt9xtZAhAqLGHqZyl/0, createdBy=42891977006, createdName=1e17414fm02(暂无匿称), createdTime=Thu Jul 26 10:02:51 CST 2018, time=2018-07-26, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1709074, encodeId=41e01e0907469, content=<a href='/topic/show?id=e50536093aa' target=_blank style='color:#2F92EE;'>#单一疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36093, encryptionId=e50536093aa, topicName=单一疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba7e31580307, createdName=thinkibmz_44722604, createdTime=Thu Mar 28 23:55:00 CST 2019, time=2019-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932631, encodeId=441b19326311c, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Thu Feb 21 06:55:00 CST 2019, time=2019-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336856, encodeId=56e6336856cb, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7ceOChkqicg6SzjqymjoEtLx55A9HNpmV1quNDdicpmTPZp1WXCq35u64iaCjRhibmrEPN5JHdvOZt9Ajj4MxzLbJ9/0, createdBy=ddf3111026, createdName=jawel, createdTime=Mon Aug 06 17:51:20 CST 2018, time=2018-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295889, encodeId=ae6b129588923, content=<a href='/topic/show?id=f30a4441598' target=_blank style='color:#2F92EE;'>#头颈癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44415, encryptionId=f30a4441598, topicName=头颈癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Sat Jul 28 00:55:00 CST 2018, time=2018-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1346836, encodeId=7c52134683662, content=<a href='/topic/show?id=97141390e89' target=_blank style='color:#2F92EE;'>#PD-1单抗KEYTRUDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13907, encryptionId=97141390e89, topicName=PD-1单抗KEYTRUDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f76619, createdName=gj0731, createdTime=Sat Jul 28 00:55:00 CST 2018, time=2018-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364847, encodeId=a172136484ec4, content=<a href='/topic/show?id=da511390508' target=_blank style='color:#2F92EE;'>#PD-1单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13905, encryptionId=da511390508, topicName=PD-1单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Sat Jul 28 00:55:00 CST 2018, time=2018-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378184, encodeId=f65613e818483, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Jul 28 00:55:00 CST 2018, time=2018-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334299, encodeId=0d6c334299dd, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfBfgWn9nXBgH1sNSiaOAKhsKpN40jDHQKqcRzovau5VibLvREN8uxnu9sKoScBicHSiaDMmbveibFdrBiaD4k4IOPwlG/0, createdBy=b5d11730951, createdName=Jackie Li, createdTime=Thu Jul 26 11:48:46 CST 2018, time=2018-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334288, encodeId=efee334288eb, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfDEeydJz0GlP8O0ngrUX6AYCXFic0XDOOAyeQicIqnOd4TrWSwiagJrsFNYuWC1Uc6iavbS1hWt9xtZAhAqLGHqZyl/0, createdBy=42891977006, createdName=1e17414fm02(暂无匿称), createdTime=Thu Jul 26 10:02:51 CST 2018, time=2018-07-26, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1709074, encodeId=41e01e0907469, content=<a href='/topic/show?id=e50536093aa' target=_blank style='color:#2F92EE;'>#单一疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36093, encryptionId=e50536093aa, topicName=单一疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba7e31580307, createdName=thinkibmz_44722604, createdTime=Thu Mar 28 23:55:00 CST 2019, time=2019-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932631, encodeId=441b19326311c, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Thu Feb 21 06:55:00 CST 2019, time=2019-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336856, encodeId=56e6336856cb, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7ceOChkqicg6SzjqymjoEtLx55A9HNpmV1quNDdicpmTPZp1WXCq35u64iaCjRhibmrEPN5JHdvOZt9Ajj4MxzLbJ9/0, createdBy=ddf3111026, createdName=jawel, createdTime=Mon Aug 06 17:51:20 CST 2018, time=2018-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295889, encodeId=ae6b129588923, content=<a href='/topic/show?id=f30a4441598' target=_blank style='color:#2F92EE;'>#头颈癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44415, encryptionId=f30a4441598, topicName=头颈癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Sat Jul 28 00:55:00 CST 2018, time=2018-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1346836, encodeId=7c52134683662, content=<a href='/topic/show?id=97141390e89' target=_blank style='color:#2F92EE;'>#PD-1单抗KEYTRUDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13907, encryptionId=97141390e89, topicName=PD-1单抗KEYTRUDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f76619, createdName=gj0731, createdTime=Sat Jul 28 00:55:00 CST 2018, time=2018-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364847, encodeId=a172136484ec4, content=<a href='/topic/show?id=da511390508' target=_blank style='color:#2F92EE;'>#PD-1单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13905, encryptionId=da511390508, topicName=PD-1单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Sat Jul 28 00:55:00 CST 2018, time=2018-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378184, encodeId=f65613e818483, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Jul 28 00:55:00 CST 2018, time=2018-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334299, encodeId=0d6c334299dd, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfBfgWn9nXBgH1sNSiaOAKhsKpN40jDHQKqcRzovau5VibLvREN8uxnu9sKoScBicHSiaDMmbveibFdrBiaD4k4IOPwlG/0, createdBy=b5d11730951, createdName=Jackie Li, createdTime=Thu Jul 26 11:48:46 CST 2018, time=2018-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334288, encodeId=efee334288eb, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfDEeydJz0GlP8O0ngrUX6AYCXFic0XDOOAyeQicIqnOd4TrWSwiagJrsFNYuWC1Uc6iavbS1hWt9xtZAhAqLGHqZyl/0, createdBy=42891977006, createdName=1e17414fm02(暂无匿称), createdTime=Thu Jul 26 10:02:51 CST 2018, time=2018-07-26, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1709074, encodeId=41e01e0907469, content=<a href='/topic/show?id=e50536093aa' target=_blank style='color:#2F92EE;'>#单一疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36093, encryptionId=e50536093aa, topicName=单一疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba7e31580307, createdName=thinkibmz_44722604, createdTime=Thu Mar 28 23:55:00 CST 2019, time=2019-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932631, encodeId=441b19326311c, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Thu Feb 21 06:55:00 CST 2019, time=2019-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336856, encodeId=56e6336856cb, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7ceOChkqicg6SzjqymjoEtLx55A9HNpmV1quNDdicpmTPZp1WXCq35u64iaCjRhibmrEPN5JHdvOZt9Ajj4MxzLbJ9/0, createdBy=ddf3111026, createdName=jawel, createdTime=Mon Aug 06 17:51:20 CST 2018, time=2018-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295889, encodeId=ae6b129588923, content=<a href='/topic/show?id=f30a4441598' target=_blank style='color:#2F92EE;'>#头颈癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44415, encryptionId=f30a4441598, topicName=头颈癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Sat Jul 28 00:55:00 CST 2018, time=2018-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1346836, encodeId=7c52134683662, content=<a href='/topic/show?id=97141390e89' target=_blank style='color:#2F92EE;'>#PD-1单抗KEYTRUDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13907, encryptionId=97141390e89, topicName=PD-1单抗KEYTRUDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f76619, createdName=gj0731, createdTime=Sat Jul 28 00:55:00 CST 2018, time=2018-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364847, encodeId=a172136484ec4, content=<a href='/topic/show?id=da511390508' target=_blank style='color:#2F92EE;'>#PD-1单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13905, encryptionId=da511390508, topicName=PD-1单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Sat Jul 28 00:55:00 CST 2018, time=2018-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378184, encodeId=f65613e818483, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Jul 28 00:55:00 CST 2018, time=2018-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334299, encodeId=0d6c334299dd, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfBfgWn9nXBgH1sNSiaOAKhsKpN40jDHQKqcRzovau5VibLvREN8uxnu9sKoScBicHSiaDMmbveibFdrBiaD4k4IOPwlG/0, createdBy=b5d11730951, createdName=Jackie Li, createdTime=Thu Jul 26 11:48:46 CST 2018, time=2018-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334288, encodeId=efee334288eb, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfDEeydJz0GlP8O0ngrUX6AYCXFic0XDOOAyeQicIqnOd4TrWSwiagJrsFNYuWC1Uc6iavbS1hWt9xtZAhAqLGHqZyl/0, createdBy=42891977006, createdName=1e17414fm02(暂无匿称), createdTime=Thu Jul 26 10:02:51 CST 2018, time=2018-07-26, status=1, ipAttribution=)]
    2018-07-26 Jackie Li

    学习

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1709074, encodeId=41e01e0907469, content=<a href='/topic/show?id=e50536093aa' target=_blank style='color:#2F92EE;'>#单一疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36093, encryptionId=e50536093aa, topicName=单一疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba7e31580307, createdName=thinkibmz_44722604, createdTime=Thu Mar 28 23:55:00 CST 2019, time=2019-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932631, encodeId=441b19326311c, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Thu Feb 21 06:55:00 CST 2019, time=2019-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336856, encodeId=56e6336856cb, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7ceOChkqicg6SzjqymjoEtLx55A9HNpmV1quNDdicpmTPZp1WXCq35u64iaCjRhibmrEPN5JHdvOZt9Ajj4MxzLbJ9/0, createdBy=ddf3111026, createdName=jawel, createdTime=Mon Aug 06 17:51:20 CST 2018, time=2018-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295889, encodeId=ae6b129588923, content=<a href='/topic/show?id=f30a4441598' target=_blank style='color:#2F92EE;'>#头颈癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44415, encryptionId=f30a4441598, topicName=头颈癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Sat Jul 28 00:55:00 CST 2018, time=2018-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1346836, encodeId=7c52134683662, content=<a href='/topic/show?id=97141390e89' target=_blank style='color:#2F92EE;'>#PD-1单抗KEYTRUDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13907, encryptionId=97141390e89, topicName=PD-1单抗KEYTRUDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f76619, createdName=gj0731, createdTime=Sat Jul 28 00:55:00 CST 2018, time=2018-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364847, encodeId=a172136484ec4, content=<a href='/topic/show?id=da511390508' target=_blank style='color:#2F92EE;'>#PD-1单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13905, encryptionId=da511390508, topicName=PD-1单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Sat Jul 28 00:55:00 CST 2018, time=2018-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378184, encodeId=f65613e818483, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Jul 28 00:55:00 CST 2018, time=2018-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334299, encodeId=0d6c334299dd, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfBfgWn9nXBgH1sNSiaOAKhsKpN40jDHQKqcRzovau5VibLvREN8uxnu9sKoScBicHSiaDMmbveibFdrBiaD4k4IOPwlG/0, createdBy=b5d11730951, createdName=Jackie Li, createdTime=Thu Jul 26 11:48:46 CST 2018, time=2018-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334288, encodeId=efee334288eb, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfDEeydJz0GlP8O0ngrUX6AYCXFic0XDOOAyeQicIqnOd4TrWSwiagJrsFNYuWC1Uc6iavbS1hWt9xtZAhAqLGHqZyl/0, createdBy=42891977006, createdName=1e17414fm02(暂无匿称), createdTime=Thu Jul 26 10:02:51 CST 2018, time=2018-07-26, status=1, ipAttribution=)]
    2018-07-26 1e17414fm02(暂无匿称)

    学习

    0

相关资讯

NICE批准默沙东的Keytruda用于治疗膀胱癌

英国国家卫生与保健优化研究所(NICE)批准默沙东(MSD)的PD-1免疫治疗药物Keytruda(pembrolizumab)用于治疗顺铂等化疗药物无效的局部晚期和转移尿路上皮癌患者。

FDA授予Keytruda优先审查

FDA已接受Merck公司的抗PD-1药物Keytruda与Eli Lilly的Alimta(培美曲塞)和铂类化疗(卡铂或顺铂)联合作为转移性非鳞状细胞非小细胞肺癌(NSCLC)一线治疗。协会还对该申请给予优先审查。该补充申请基于第3期KEYNOTE-189试验的总生存期(OS)和无进展生存期(PFS)数据。KEYNOTE-189是KEYNOTE-021(队列G)的一项验证性试验,是Keytrud

Keytruda被批准用于又一种血癌

美国监管机构再次扩大了MSD免疫疗法Keytruda的批准使用清单,为治疗原发性纵隔大B细胞淋巴瘤(PMBCL)发出了绿灯。作为对血液恶性肿瘤的第二次批准,Keytruda (pembrolizumab)现在可以用于治疗顽固性原发性PMBCL(一种非霍奇金淋巴瘤)的患者,或者在两种或更多以前的治疗后复发的患者。这一决定使PMBCL患者能够获得针对其病情的首个抗PD-1疗法。根据KEYNOTE-17

重磅!默沙东Keytruda获批,第2个PD-1药物正式登陆中国

2018年7月25日,默沙东PD-1单抗Keytruda(帕博利珠单抗)的中国上市申请(JXSS1800002)正式获得国家药品监督管理局批准,成为继百时美施贵宝Opdivo之后第2个正式在中国上市的PD-1/PD-L1单抗类药物(见:重磅!Opdivo在中国正式获批上市!定价猜想……)。Keytruda的中国上市时间比Opdivo晚了1个多月,但二者适应症不同。Opdivo用于二线治疗非小细胞肺

NICE认为MSD的Keytruda作为一线肺癌治疗具有成本效益

MSD的Keytruda将会在英国国民健康保险制度上为之前未经治疗的转移性非小细胞肺癌患者提供,英国国家医疗服务体系(NHS England)与该公司达成了一项协议,通过NICE,以确保其成本效益。在最终指南中,NICE批准了常规NHS资助,用于在未经治疗的PD-L1阳性转移性非小细胞肺癌(NSCLC)的成人中使用该药物,该药未经表皮生长因子受体或间变性淋巴瘤激酶阳性突变。但该报告称,在连续治疗两

欧盟审查MSD的Keytruda / chemo组合

欧洲的监管机构已经开始对MSD的Keytruda/pemetrexed组合进行审查,以治疗转移性非小细胞肺癌(NSCLC)患者的一线治疗。这项申请是基于第三阶段KEYNOTE-189试验的数据,该试验显示,Keytruda (pembrolizumab)与pemetrexed (Lilly 's Alimta)和顺铂或卡铂联合使用的一线使用比单独使用化疗降低了51%的死亡风险。该公司指出,无论PD

Baidu
map
Baidu
map
Baidu
map